Home
/
Maze Therapeutics, Inc.
/
Financials
/
Quarterly
Maze Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Maze Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2025
Jun 30, 2025
$0
Aug 12, 2025
Q3
2025
Sep 30, 2024
$2.50M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$165.00M
Aug 12, 2025
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($30.09M)
Nov 6, 2025
Q3
2025
Jun 30, 2025
($33.68M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($33.68M)
Aug 12, 2025
Q3
2025
Mar 31, 2025
($32.79M)
Nov 6, 2025
Q2
2025
Mar 31, 2025
($32.79M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($32.79M)
May 14, 2025
Q3
2025
Sep 30, 2024
($24.75M)
Nov 6, 2025
Q3
2025
Jun 30, 2024
$139.06M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$139.06M
Aug 12, 2025
Q2
2025
Mar 31, 2024
($32.49M)
Aug 12, 2025
Q3
2025
Mar 31, 2024
($32.49M)
Nov 6, 2025
Q1
2025
Mar 31, 2024
($32.49M)
May 14, 2025
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($32.97M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($36.47M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($35.40M)
May 14, 2025
Q3
2025
Sep 30, 2024
($24.23M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
$139.56M
Aug 12, 2025
Q1
2025
Mar 31, 2024
($28.01M)
May 14, 2025